Cancer Drug Resistance Launches 2025 Second Round of Early-Career Editorial Board Recruitment

Join CDR and Help Shape the Future of Cancer Research Publishing

About CDR

In 2025, Cancer Drug Resistance (CDR) achieved an Impact Factor of 5.2, placing it in the top 20% of Q1 oncology journals in JCR, and a CiteScore of 8.3, ranking in Q1 for pharmacology journals. As the only global journal exclusively focused on cancer drug resistance, CDR plays a pivotal role in advancing understanding and management of therapeutic resistance in oncology.

To enhance academic vitality, foster next-generation editorial talent, and strengthen the journal’s global influence, CDR is launching its second round of 2025 global recruitment for Early-Career Editorial Board (ECEB) members. We warmly invite outstanding young researchers dedicated to overcoming cancer drug resistance to join us in shaping the future of the field.

Qualifications & Areas of Interest

1. Academic Integrity: Strong commitment to rigorous scientific standards and research ethics.

2. Research Focus:  Demonstrated expertise in cancer drug resistance or related interdisciplinary areas. Priority domains include:

• Computational Resistance Biology & Artificial Intelligence: Multi-omics integration, machine learning, resistance prediction; biomarker discovery, drug combination strategies.
• Microbiome-Cancer Therapy Interactions: Gut and tumor microbiome modulation of therapy resistance.
• Neuro-Tumor Interactions: Neural infiltration and neurotransmitter signaling in resistance.
• Immunotherapy Resistance: Mechanisms of immune checkpoint inhibitor (ICI) resistance, CAR-T/NK cell dysfunction and exhaustion.
• Cancer Stem Cells: Roles in recurrence, metastasis, and multi-therapy resistance.
• Radioresistance & Radiosensitization: DNA repair, tumor hypoxia, novel radiosensitizers.
• Liquid Biopsy & Clinical Monitoring: ctDNA, CTCs, clonal evolution tracking.
• Resistance in Rare or Hard-to-Treat Cancers: e.g., head and neck squamous cell carcinoma (HNSCC), thyroid cancer, tongue squamous cell carcinoma (TSCC).
• Targeted Therapy Resistance: Tyrosine kinase inhibitors (TKIs) and resistance management.
• Molecular Pharmacology & Drug Design: Targeting resistance mechanisms.
• DNA Damage Response & Epigenetic Regulation: Therapeutic targeting of resistance.
• Drug Delivery & Nanomedicine: Overcoming barriers and enhancing drug targeting.
• Clinical & Translational Research: Biomarker-driven trials, precision oncology.

3. Age & Credentials: Generally under 40; PhD or equivalent senior academic rank (Associate Professor or above).

4. Research Output: At least five SCI-indexed first- or corresponding-author publications in the past three years in oncology, pharmacology, or drug resistance.

5. Outstanding Achievements: Publications in top-tier journals (Nature, Science, Cell, etc.) preferred; partial relaxation possible for exceptional candidates.

6. International Experience: Overseas research or prior reviewer/editorial experience preferred.

7. Professional Competence: Strong academic standing, excellent English writing skills, peer review, editorial, or Special Issue experience.

8. Commitment: Alignment with CDR’s mission and willingness to actively contribute.

Benefits of Joining the ECEB

1. Official Recognition

• One-year renewable appointment certificate;
• “Outstanding ECEB Member” awards for top contributors.

2. Academic Engagement & Visibility

• Participation in peer review;
• Opportunities to serve as Guest Editor;
• Priority invitations to CDR-hosted events.

3. Financial and Publication Support

• Article Processing Charge (APC) discounts for completed reviews (valid for two years);
• Travel grants (USD 300–1,000) for promoting CDR at approved international conferences.

4. Publication & Promotion Advantages

• Fast-track review for submissions by members or their recommended authors.
• Visibility through the CDR website and social media highlights.

5. Career Development

• Opportunities to collaborate with Editors-in-Chief, Associate Editors, and global experts to advance research influence.

Roles & Responsibilities

1. Scholarly Outreach & Promotion

• Promote CDR at institutions, conferences, and academic platforms.

2. Peer-Review Duties

• Provide at least five in-depth manuscript reviews annually.

3. Meetings & Special Issues

• Participate in board meetings and events;
• Lead thematic Special Issues and recommend new editorial candidates.

4. Networking & Collaboration

• Recommend experts from Europe and North America.
• Assist in organizing academic meetings and expanding the author pool.

How to Apply

1. Submit Application: Complete the CDR ECEB Application Form and upload your CV.

2. Selection process: Application → Initial Review → Email notification within 10 working days. Probationary contributions (reviews, promotion efforts) will determine formal appointment.

The CDR Early-Career Editorial Board looks forward to welcoming you to our global team. Together, we can advance the frontiers of cancer drug resistance research!

Editor: Suri
Language Editor:  Catherine Yang
Production Editor: Ting Xu
Respectfully Submitted by the Editorial Office of Cancer Drug Resistance